Abstract
Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full potential of this platform necessitates innovative molecular designs to tackle several clinical challenges such as drug resistance, tumour heterogeneity and treatment-related adverse effects. Several emerging ADC formats exist, including bispecific ADCs, conditionally active ADCs (also known as probody–drug conjugates), immune-stimulating ADCs, protein-degrader ADCs and dual-drug ADCs, and each offers unique capabilities for tackling these various challenges. For example, probody–drug conjugates can enhance tumour specificity, whereas bispecific ADCs and dual-drug ADCs can address resistance and heterogeneity with enhanced activity. The incorporation of immune-stimulating and protein-degrader ADCs, which have distinct mechanisms of action, into existing treatment strategies could enable multimodal cancer treatment. Despite the promising outlook, the importance of patient stratification and biomarker identification cannot be overstated for these emerging ADCs, as these factors are crucial to identify patients who are most likely to derive benefit. As we continue to deepen our understanding of tumour biology and refine ADC design, we will edge closer to developing truly effective and safe ADCs for patients with treatment-refractory cancers. In this Review, we highlight advances in each ADC component (the monoclonal antibody, payload, linker and conjugation chemistry) and provide more-detailed discussions on selected examples of emerging novel ADCs of each format, enabled by engineering of one or more of these components.
Key points
-
Antibody–drug conjugates (ADCs) are an effective cancer therapy, although responses to these agents are often limited by acquired resistance and treatment-related adverse effects.
-
Advances in the various ADC components (namely the antibody, linker, payload and conjugation chemistry) will be key to improving both the efficacy and safety of these agents.
-
To address these challenges, several novel ADC formats have been developed, including bispecific ADCs, probody–drug conjugates, immune-stimulating ADCs, protein-degrader ADCs and dual-drug ADCs.
-
Probody–drug conjugates are expected to have improved tumour specificity, whereas bispecific ADCs and dual-drug ADCs have the potential to combat drug resistance and tumour heterogeneity.
-
Integrating immune-stimulating ADCs and protein-degrader ADCs with current treatment regimens might enable multimodal treatment, potentially through several distinct mechanisms of action.
-
Patient stratification and biomarker identification will be crucial to maximize the clinical benefits of these emerging ADCs.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
£14.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
£139.00 per year
only £11.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Drago, J. Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol. 18, 327–344 (2021).
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M. & Beck, A. Antibody–drug conjugates come of age in oncology. Nat. Rev. Drug. Discov. 22, 641–661 (2023).
Tarantino, P., Ricciuti, B., Pradhan, S. M. & Tolaney, S. M. Optimizing the safety of antibody–drug conjugates for patients with solid tumours. Nat. Rev. Clin. Oncol. 20, 558–576 (2023).
Beck, A., Goetsch, L., Dumontet, C. & Corvaïa, N. Strategies and challenges for the next generation of antibody–drug conjugates. Nat. Rev. Drug. Discov. 16, 315–337 (2017).
Maecker, H., Jonnalagadda, V., Bhakta, S., Jammalamadaka, V. & Junutula, J. R. Exploration of the antibody–drug conjugate clinical landscape. MAbs 15, 2229101 (2023).
Grand View Research. Antibody Drug Conjugates Market Size, Share & Trends Analysis Report by Application (Blood Cancer, Breast Cancer), by Technology ({Type-Cleavable, Non-Cleavable}), by Region, and Segment Forecasts, 2023–2030, https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market (2024).
Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81–94 (2018).
Loganzo, F., Sung, M. & Gerber, H.-P. Mechanisms of resistance to antibody–drug conjugates. Mol. Cancer Ther. 15, 2825–2834 (2016).
García-Alonso, S., Ocaña, A. & Pandiella, A. Resistance to antibody–drug conjugates. Cancer Res. 78, 2159–2165 (2018).
Norsworthy, K. J. et al. FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia. Oncologist 23, 1103–1108 (2018).
Ricart, A. D. Antibody–drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin. Cancer Res. 17, 6417–6427 (2011).
Yu, J., Song, Y. & Tian, W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J. Hematol. Oncol. 13, 45 (2020).
Hock, M. B., Thudium, K. E., Carrasco-Triguero, M. & Schwabe, N. F. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J. 17, 35–43 (2015).
Gorovits, B. & Krinos-Fiorotti, C. Proposed mechanism of off-target toxicity for antibody–drug conjugates driven by mannose receptor uptake. Cancer Immunol. Immunother. 62, 217–223 (2013).
Yamazoe, S. et al. Impact of drug conjugation on thermal and metabolic stabilities of aglycosylated and N-glycosylated antibodies. Bioconjug. Chem. 33, 576–585 (2022).
Gutierrez, C. & Schiff, R. HER2: biology, detection, and clinical implications. Arch. Pathol. Lab. Med. 135, 55–62 (2011).
Stepan, L. P. et al. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J. Histochem. Cytochem. 59, 701–710 (2011).
Pegram, M. D. et al. First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody–drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer. Mol. Cancer Ther. 20, 1442–1453 (2021).
Le Joncour, V. et al. A novel anti-HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine. Mol. Cancer Ther. 18, 1721–1730 (2019).
Mersana Therapeutics. Mersana Therapeutics announces partial clinical hold for XMT-1522 clinical trial. https://ir.mersana.com/news-releases/news-release-details/mersana-therapeutics-announces-partial-clinical-hold-xmt-1522 (2018).
Duvall, J. R. et al. XMT-2056, a HER2-targeted immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab. Cancer Res. 82 (Suppl. 12), Abstr. 3503 (2022).
Mersana Therapeutics. Mersana Therapeutics announces clinical hold on XMT-2056 phase 1 clinical trial. https://ir.mersana.com/news-releases/news-release-details/mersana-therapeutics-announces-clinical-hold-xmt-2056-phase-1 (2023).
King, G. T. et al. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Invest. New Drugs 36, 836–847 (2018).
Gan, H. K., Cvrljevic, A. N. & Johns, T. G. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. 280, 5350–5370 (2013).
Phillips, A. C. et al. ABT-414, an antibody–drug conjugate targeting a tumor-selective EGFR epitope. Mol. Cancer Ther. 15, 661–669 (2016).
Trerotola, M. et al. Trop-2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis. Neoplasia 23, 415–428 (2021).
Alberti, S., Trerotola, M. & Guerra, E. The Hu2G10 tumor-selective anti-Trop-2 monoclonal antibody targets the cleaved-activated Trop-2 and shows therapeutic efficacy against multiple human cancers. Cancer Res. 82 (Suppl. 12), Abstr. 340 (2022).
Kim, H. et al. LCB84, a TROP2-targeted ADC, for treatment of solid tumors that express TROP-2 using the hu2G10 tumor-selective anti-TROP2 monoclonal antibody, a proprietary site-directed conjugation technology and plasma-stable tumor-selective linker chemistry. Cancer Res. 82 (Suppl. 12), Abstr. 328 (2022).
Li, C.-W. et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell 33, 187–201.e10 (2018).
de Goeij, B. E. C. G. et al. High turnover of tissue factor enables efficient intracellular delivery of antibody–drug conjugates. Mol. Cancer Ther. 14, 1130–1140 (2015).
Thurber, G. M., Schmidt, M. M. & Wittrup, K. D. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug. Deliv. Rev. 60, 1421–1434 (2008).
Adams, G. P. et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61, 4750–4755 (2001).
Samantasinghar, A. et al. A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed. Pharmacother. 161, 114408 (2023).
Yadav, A., Mandal, M. K. & Dubey, K. K. In vitro cytotoxicity study of cyclophosphamide, etoposide and paclitaxel on monocyte macrophage cell line raw 264.7. Indian J. Microbiol. 60, 511–517 (2020).
Tumey, L. N. et al. Optimization of tubulysin antibody–drug conjugates: a case study in addressing ADC metabolism. ACS Med. Chem. Lett. 7, 977–982 (2016).
Staben, L. R. et al. Stabilizing a tubulysin antibody–drug conjugate to enable activity against multidrug-resistant tumors. ACS Med. Chem. Lett. 8, 1037–1041 (2017).
Burke, P. J. et al. Glucuronide-linked antibody–tubulysin conjugates display activity in MDR+ and heterogeneous tumor models. Mol. Cancer Ther. 17, 1752–1760 (2018).
Hamilton, J. Z. et al. Improving antibody–tubulysin conjugates through linker chemistry and site-specific conjugation. ChemMedChem 16, 1077–1081 (2021).
Rottey, S. et al. Phase I/IIa trial of BMS-986148, an anti-mesothelin antibody–drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors. Clin. Cancer Res. 28, 95–105 (2022).
Yao, H.-P., Zhao, H., Hudson, R., Tong, X.-M. & Wang, M.-H. Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: pharmaceutical strategy and clinical progress. Drug Discov. Today 26, 1857–1874 (2021).
Yu, S.-F. et al. A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs. Clin. Cancer Res. 21, 3298–3306 (2015).
Stefan, N. et al. Highly potent, anthracycline-based antibody-drug conjugates generated by enzymatic, site-specific conjugation. Mol. Cancer Ther. 16, 879–892 (2017).
Holte, D. et al. Evaluation of PNU-159682 antibody drug conjugates (ADCs). Bioorg. Med. Chem. Lett. 30, 127640 (2020).
Pahl, A., Lutz, C. & Hechler, T. Amanitins and their development as a payload for antibody-drug conjugates. Drug Discov. Today Technol. 30, 85–89 (2018).
Liu, Y. et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 520, 697–701 (2015).
Vaisitti, T. et al. Anti-CD37 α-amanitin-conjugated antibodies as potential therapeutic weapons for Richter syndrome. Blood 140, 1565–1569 (2022).
Ackerman, S. E. et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat. Cancer 2, 18–33 (2021).
Hong, K. B. & An, H. Degrader–antibody conjugates: emerging new modality. J. Med. Chem. 66, 140–148 (2023).
Khera, E. et al. Cellular-resolution imaging of bystander payload tissue penetration from antibody–drug conjugates. Mol. Cancer Ther. 21, 310–321 (2022).
Staudacher, A. H. & Brown, M. P. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br. J. Cancer 117, 1736–1742 (2017).
Dei, S., Braconi, L., Romanelli, M. N. & Teodori, E. Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators. Cancer Drug Resist. 2, 710–743 (2019).
Buecheler, J. W., Winzer, M., Tonillo, J., Weber, C. & Gieseler, H. Impact of payload hydrophobicity on the stability of antibody–drug conjugates. Mol. Pharm. 15, 2656–2664 (2018).
Lyon, R. P. et al. Reducing hydrophobicity of homogeneous antibody–drug conjugates improves pharmacokinetics and therapeutic index. Nat. Biotechnol. 33, 733–735 (2015).
Lundahl, M. L. E., Fogli, S., Colavita, P. E. & Scanlan, E. M. Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies. RSC Chem. Biol. 2, 1004–1020 (2021).
Lyski, R. D. et al. Development of novel antibody–camptothecin conjugates. Mol. Cancer Ther. 20, 329–339 (2021).
Simmons, J. K., Burke, P. J., Cochran, J. H., Pittman, P. G. & Lyon, R. P. Reducing the antigen-independent toxicity of antibody–drug conjugates by minimizing their non-specific clearance through PEGylation. Toxicol. Appl. Pharmacol. 392, 114932 (2020).
Meyer, D. W. et al. An in vitro assay using cultured Kupffer cells can predict the impact of drug conjugation on in vivo antibody pharmacokinetics. Mol. Pharm. 17, 802–809 (2020).
Zhao, H. et al. Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody–drug conjugates. Cancer Res. 78, 2115–2126 (2018).
Zhao, H. et al. Inhibition of megakaryocyte differentiation by antibody–drug conjugates (ADCs) is mediated by macropinocytosis: implications for ADC-induced thrombocytopenia. Mol. Cancer Ther. 16, 1877–1886 (2017).
Guffroy, M. et al. Liver microvascular injury and thrombocytopenia of antibody–calicheamicin conjugates in cynomolgus monkeys—mechanism and monitoring. Clin. Cancer Res. 23, 1760–1770 (2017).
Burke, P. J. et al. Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody-drug conjugates. Mol. Cancer Ther. 16, 116–123 (2017).
Ochtrop, P. et al. Compact hydrophilic electrophiles enable highly efficacious high DAR ADCs with excellent in vivo PK profile. Chem. Sci. 14, 2259–2266 (2023).
Viricel, W. et al. Monodisperse polysarcosine-based highly-loaded antibody–drug conjugates. Chem. Sci. 10, 4048–4053 (2019).
Hu, Y., Hou, Y., Wang, H. & Lu, H. Polysarcosine as an alternative to PEG for therapeutic protein conjugation. Bioconjug. Chem. 29, 2232–2238 (2018).
Conilh, L. et al. Exatecan antibody drug conjugates based on a hydrophilic polysarcosine drug-linker platform. Pharmaceuticals 14, 247 (2021).
Weng, W. et al. Antibody–exatecan conjugates with a novel self-immolative moiety overcome resistance in colon and lung cancer. Cancer Discov. 13, 950–973 (2023).
Tsuchikama, K. & An, Z. Antibody–drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9, 33–46 (2018).
Su, D. & Zhang, D. Linker design impacts antibody–drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency. Front. Pharmacol. 12, 687926 (2021).
Baah, S., Laws, M. & Rahman, K. M. Antibody–drug conjugates—a tutorial review. Molecules 26, 2943 (2021).
Ogitani, Y. et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res. 22, 5097–5108 (2016).
Anami, Y. et al. Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice. Nat. Commun. 9, 2512 (2018).
Yamazaki, C. M. et al. Antibody–drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat. Commun. 12, 3528 (2021).
Ha, S. Y. Y. et al. An enzymatically cleavable tripeptide linker for maximizing the therapeutic index of antibody–drug conjugates. Mol. Cancer Ther. 21, 1449–1461 (2022).
Jeffrey, S. C. et al. Development and properties of beta-glucuronide linkers for monoclonal antibody–drug conjugates. Bioconjug. Chem. 17, 831–840 (2006).
Chuprakov, S. et al. Tandem-cleavage linkers improve the in vivo stability and tolerability of antibody–drug conjugates. Bioconjug. Chem. 32, 746–754 (2021).
Bargh, J. D. et al. Sulfatase-cleavable linkers for antibody–drug conjugates. Chem. Sci. 11, 2375–2380 (2020).
Kern, J. C. et al. Discovery of pyrophosphate diesters as tunable, soluble, and bioorthogonal linkers for site-specific antibody–drug conjugates. J. Am. Chem. Soc. 138, 1430–1445 (2016).
Lerchen, H.-G. et al. Tailored linker chemistries for the efficient and selective activation of ADCs with KSPi payloads. Bioconjug. Chem. 31, 1893–1898 (2020).
Miller, J. T., Vitro, C. N., Fang, S., Benjamin, S. R. & Tumey, L. N. Enzyme-agnostic lysosomal screen identifies new legumain-cleavable ADC linkers. Bioconjug. Chem. 32, 842–858 (2021).
Junutula, J. R. et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26, 925–932 (2008).
Axup, J. Y. et al. Synthesis of site-specific antibody–drug conjugates using unnatural amino acids. Proc. Natl Acad. Sci. USA 109, 16101–16106 (2012).
Zimmerman, E. S. et al. Production of site-specific antibody–drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug. Chem. 25, 351–361 (2014).
VanBrunt, M. P. et al. Genetically encoded azide containing amino acid in mammalian cells enables site-specific antibody–drug conjugates using click cycloaddition chemistry. Bioconjug. Chem. 26, 2249–2260 (2015).
Bryden, F. et al. Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment. Bioconjug. Chem. 25, 611–617 (2014).
Schumacher, F. F. et al. Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging. Org. Biomol. Chem. 12, 7261–7269 (2014).
Behrens, C. R. et al. Antibody–drug conjugates (ADCs) derived from interchain cysteine cross-linking demonstrate improved homogeneity and other pharmacological properties over conventional heterogeneous ADCs. Mol. Pharm. 12, 3986–3998 (2015).
Maruani, A. et al. A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. Nat. Commun. 6, 6645 (2015).
Bahou, C. et al. Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones. Org. Biomol. Chem. 16, 1359–1366 (2018).
Forte, N., Chudasama, V. & Baker, J. R. Homogeneous antibody–drug conjugates via site-selective disulfide bridging. Drug Discov. Today Technol. 30, 11–20 (2018).
Fujii, T. et al. AJICAP second generation: improved chemical site-specific conjugation technology for antibody–drug conjugate production. Bioconjug. Chem. 34, 728–738 (2023).
Zhou, Q. et al. Site-specific antibody–drug conjugation through glycoengineering. Bioconjug. Chem. 25, 510–520 (2014).
van Geel, R. et al. Chemoenzymatic conjugation of toxic payloads to the globally conserved N-glycan of native mAbs provides homogeneous and highly efficacious antibody-drug conjugates. Bioconjug. Chem. 26, 2233–2242 (2015).
Manabe, S. et al. Characterization of antibody products obtained through enzymatic and nonenzymatic glycosylation reactions with a glycan oxazoline and preparation of a homogeneous antibody-drug conjugate via Fc N-glycan. Bioconjug. Chem. 30, 1343–1355 (2019).
de Bever, L. et al. Generation of DAR1 antibody–drug conjugates for ultrapotent payloads using tailored GlycoConnect technology. Bioconjug. Chem. 34, 538–548 (2023).
Jeger, S. et al. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew. Chem. Int. Ed. Engl. 49, 9995–9997 (2010).
Strop, P. et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol. 20, 161–167 (2013).
Dennler, P. et al. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody–drug conjugates. Bioconjug. Chem. 25, 569–578 (2014).
Anami, Y. et al. Enzymatic conjugation using branched linkers for constructing homogeneous antibody–drug conjugates with high potency. Org. Biomol. Chem. 15, 5635–5642 (2017).
Rabuka, D., Rush, J. S., deHart, G. W., Wu, P. & Bertozzi, C. R. Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat. Protoc. 7, 1052–1067 (2012).
Drake, P. M. et al. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug. Chem. 25, 1331–1341 (2014).
Beerli, R. R., Hell, T., Merkel, A. S. & Grawunder, U. Sortase enzyme-mediated generation of site-specifically conjugated antibody drug conjugates with high in vitro and in vivo potency. PLoS ONE 10, e0131177 (2015).
Pan, L. et al. Sortase A-generated highly potent anti-CD20–MMAE conjugates for efficient elimination of B-lineage lymphomas. Small 13, 1602267 (2017).
Antos, J. M. et al. Site-specific protein labeling via sortase-mediated transpeptidation. Curr. Protoc. Protein Sci. 89, 15.3.1–15.3.19 (2017).
Kontermann, R. E. & Brinkmann, U. Bispecific antibodies. Drug Discov. Today 20, 838–847 (2015).
Beishenaliev, A. et al. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: a review. J. Control. Release 359, 268–286 (2023).
Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836–847 (2017).
Linke, R., Klein, A. & Seimetz, D. Catumaxomab: clinical development and future directions. MAbs 2, 129–136 (2010).
Maruani, A. Bispecifics and antibody–drug conjugates: a positive synergy. Drug Discov. Today Technol. 30, 55–61 (2018).
Friedman, L. M. et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl Acad. Sci. USA 102, 1915–1920 (2005).
Ben-Kasus, T., Schechter, B., Lavi, S., Yarden, Y. & Sela, M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc. Natl Acad. Sci. USA 106, 3294–3299 (2009).
Li, J. Y. et al. A biparatopic HER2-targeting antibody–drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 29, 117–129 (2016).
Toader, D. et al. Structure–cytotoxicity relationships of analogues of N14-desacetoxytubulysin H. J. Med. Chem. 59, 10781–10787 (2016).
Oganesyan, V. et al. Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody. J. Biol. Chem. 293, 8439–8448 (2018).
Modi, S. et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J. Clin. Oncol. 38, 1887–1896 (2020).
Hamblett, K. J. et al. ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers. Cancer Res. 79 (Suppl. 4), Abstr. P6-17-13 (2019).
Barnscher, S. D., Rojas, A. H., Hamblett, K. J. & Escalante, N. Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer. Cancer Res. 83 (Suppl. 7), Abstr. 2633 (2023).
Hamblett, K. et al. Anti-her2 biparatopic antibody–drug conjugates and methods of use. US Patent US20210346508A1 (2021).
Weisser, N. E. et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat. Commun. 14, 1394 (2023).
Jhaveri, K. et al. 460MO preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers. Ann. Oncol. 33, S749–S750 (2022).
Katz, J., Janik, J. E. & Younes, A. Brentuximab vedotin (SGN-35). Clin. Cancer Res. 17, 6428–6436 (2011).
Palanca-Wessels, M. C. A. et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 16, 704–715 (2015).
Alt, M., Stecca, C., Tobin, S., Jiang, D. M. & Sridhar, S. S. Enfortumab vedotin in urothelial cancer. Ther. Adv. Urol. 12, 1756287220980192 (2020).
DaSilva, J. O. et al. A biparatopic antibody–drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. Mol. Cancer Ther. 20, 1966–1976 (2021).
Perez Bay, A. E. et al. A bispecific METxMET antibody-drug conjugate with cleavable linker is processed in recycling and late endosomes. Mol. Cancer Ther. 22, 357–370 (2023).
DaSilva, J. O. et al. A biparatopic antibody that modulates MET trafficking exhibits enhanced efficacy compared with parental antibodies in MET-driven tumor models. Clin. Cancer Res. 26, 1408–1419 (2020).
Drilon, A. E. et al. A phase 1/2 study of REGN5093-M114, a METxMET antibody–drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC. J. Clin. Oncol. 40, TPS8593 (2022).
Gomatou, G., Syrigos, N. & Kotteas, E. Osimertinib resistance: molecular mechanisms and emerging treatment options. Cancers 15, 841 (2023).
Cho, B. C. Dr Cho on first-line amivantamab plus lazertinib in EGFR-mutant NSCLC. OncLive https://www.onclive.com/view/dr-cho-on-the-mariposa-trial-of-first-line-amivantamab-plus-lazertinib-in-egfr-mutant-nsclc (2023).
Sellmann, C. et al. Balancing selectivity and efficacy of bispecific epidermal growth factor receptor (EGFR) × c-MET antibodies and antibody–drug conjugates. J. Biol. Chem. 291, 25106–25119 (2016).
Comer, F. et al. AZD9592: an EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond. Cancer Res. 83 (Suppl. 7), Abstr. 5736 (2023).
McGrath, L. et al. Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate. Cancer Res. 83 (Suppl. 7), Abstr. 5737 (2023).
Knuehl, C. et al. M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and EGFR co-expression. Cancer Res. 82 (Suppl. 12), Abstr. 5284 (2022).
Wan, W. et al. BL-B01D1, a novel EGFR×HER3-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation. Cancer Res. 83 (Suppl. 7), Abstr. 2642 (2023).
Sorkin, A. & Goh, L. K. Endocytosis and intracellular trafficking of ErbBs. Exp. Cell Res. 315, 683–696 (2009).
Austin, C. D. et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell 15, 5268–5282 (2004).
DeVay, R. M., Shelton, D. L. & Liang, H. Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). J. Biol. Chem. 288, 10805–10818 (2013).
DeVay, R. M., Yamamoto, L., Shelton, D. L. & Liang, H. Common proprotein convertase subtilisin/kexin type 9 (PCSK9) epitopes mediate multiple routes for internalization and function. PLoS ONE 10, e0125127 (2015).
Tuli, A. et al. Amyloid precursor-like protein 2 increases the endocytosis, instability, and turnover of the H2-K(d) MHC class I molecule. J. Immunol. 181, 1978–1987 (2008).
Tuli, A. et al. Mechanism for amyloid precursor-like protein 2 enhancement of major histocompatibility complex class I molecule degradation. J. Biol. Chem. 284, 34296–34307 (2009).
Andreev, J. et al. Bispecific antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs. Mol. Cancer Ther. 16, 681–693 (2017).
DeVay, R. M. et al. Improved lysosomal trafficking can modulate the potency of antibody drug conjugates. Bioconjug. Chem. 28, 1102–1114 (2017).
Merchant, M. et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc. Natl Acad. Sci. USA 110, E2987–E2996 (2013).
Liu, L. et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin. Cancer Res. 20, 6059–6070 (2014).
Oh, Y. M. et al. A new anti-c-Met antibody selected by a mechanism-based dual-screening method: therapeutic potential in cancer. Mol. Cell 34, 523–529 (2012).
Neijssen, J. et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J. Biol. Chem. 296, 100641 (2021).
Kim, S.-B. et al. First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody–drug conjugate (BAY 1187982) in patients with advanced cancer. Target. Oncol. 14, 591–601 (2019).
Lemech, C. et al. A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody–drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. Invest. New Drugs 38, 1815–1825 (2020).
Zhao, P. et al. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm. Sin. B 10, 1589–1600 (2020).
Rautio, J. et al. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7, 255–270 (2008).
Abet, V., Filace, F., Recio, J., Alvarez-Builla, J. & Burgos, C. Prodrug approach: an overview of recent cases. Eur. J. Med. Chem. 127, 810–827 (2017).
Rautio, J., Meanwell, N. A., Di, L. & Hageman, M. J. The expanding role of prodrugs in contemporary drug design and development. Nat. Rev. Drug Discov. 17, 559–587 (2018).
Erster, O. et al. Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J. Control. Release 161, 804–812 (2012).
Desnoyers, L. R. et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci. Transl. Med. 5, 207ra144 (2013).
Geiger, M. et al. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. Nat. Commun. 11, 3196 (2020).
Sulea, T. et al. Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironment. MAbs 12, 1682866 (2020).
Lucchi, R., Bentanachs, J. & Oller-Salvia, B. The masking game: design of activatable antibodies and mimetics for selective therapeutics and cell control. ACS Cent. Sci. 7, 724–738 (2021).
Liu, Y., Nguyen, A. W. & Maynard, J. A. Engineering antibodies for conditional activity in the solid tumor microenvironment. Curr. Opin. Biotechnol. 78, 102809 (2022).
Bleuez, C., Koch, W. F., Urbach, C., Hollfelder, F. & Jermutus, L. Exploiting protease activation for therapy. Drug Discov. Today 27, 1743–1754 (2022).
Liu, X. et al. A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering. Mol. Ther. Oncolytics 27, 256–269 (2022).
Ulisse, S., Baldini, E., Sorrenti, S. & D’Armiento, M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets 9, 32–71 (2009).
Uhland, K. Matriptase and its putative role in cancer. Cell. Mol. Life Sci. 63, 2968–2978 (2006).
LeBeau, A. M. et al. Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc. Natl Acad. Sci. USA 110, 93–98 (2013).
Liu, C., Sun, C., Huang, H., Janda, K. & Edgington, T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 63, 2957–2964 (2003).
Singh, S. et al. Nonclinical efficacy and safety of CX-2029, an anti-CD71 probody–drug conjugate. Mol. Cancer Ther. 21, 1326–1336 (2022).
CytomX Therapeutics Inc. CytomX therapeutics presents overview of conditionally-activated antibody-drug conjugate (ADC) programs including next generation EpCAM-targeting CX-2051. CytomX Press Release Details https://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-presents-overview-conditionally-activated/ (2022).
Chomet, M. et al. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice. Theranostics 10, 5815–5828 (2020).
Johnson, M. et al. Phase I, first-in-human study of the probody therapeutic CX-2029 in adults with advanced solid tumor malignancies. Clin. Cancer Res. 27, 4521–4530 (2021).
Boni, V. et al. Praluzatamab ravtansine, a CD166-targeting antibody–drug conjugate, in patients with advanced solid tumors: an open-label phase I/II trial. Clin. Cancer Res. 28, 2020–2029 (2022).
Swart, G. W. M. Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur. J. Cell Biol. 81, 313–321 (2002).
Garcia-Corbacho, J. et al. PROCLAIM-CX-2009: a first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors. Ann. Oncol. 28, v140 (2017).
Trang, V. H. et al. A coiled-coil masking domain for selective activation of therapeutic antibodies. Nat. Biotechnol. 37, 761–765 (2019).
Huang, L. et al. Preclinical evaluation of a next-generation, EGFR targeting ADC that promotes regression in KRAS or BRAF mutant tumors. Cancer Res. 76 (Suppl. 14), Abstr. 1217 (2016).
Bahn, J. D. et al. HTI-1511, a novel anti-EGFR-ADC, overcomes mutation resistance and demonstrates significant activity against multiple tumor types in preclinical studies. Cancer Res. 77 (Suppl. 13), Abstr. 50 (2017).
Kang, J. C. et al. Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy. Nat. Biotechnol. 37, 523–526 (2019).
Sharp, L. L. et al. Anti-tumor efficacy of BA3011, a novel conditionally active biologic (CAB) anti-AXL-ADC. Cancer Res. 78 (Suppl. 13), Abstr. 827 (2018).
Sharp, L. L. et al. Anti-tumor efficacy of BA3021, a novel conditionally active biologic (CAB) anti-ROR2 ADC. Cancer Res. 78 (Suppl. 13), Abstr. 833 (2018).
Khan, M. A. G. Halozyme terminates license agreement with Abzena. https://www.spglobal.com/marketintelligence/en/news-insights/blog/essential-ir-insights-newsletter-fall-2023 (2018).
Chang, H. W. et al. Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches. Proc. Natl Acad. Sci. USA 118, e2020606118 (2021).
BioAtla. CAB Portfolio. BioAtla https://www.bioatla.com/cab-portfolio/ (2016).
Seidel, J. A., Otsuka, A. & Kabashima, K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front. Oncol. 8, 86 (2018).
Urban-Wojciuk, Z. et al. The role of TLRs in anti-cancer immunity and tumor rejection. Front. Immunol. 10, 2388 (2019).
Kaczanowska, S., Joseph, A. M. & Davila, E. TLR agonists: our best frenemy in cancer immunotherapy. J. Leukoc. Biol. 93, 847–863 (2013).
Le Naour, J. & Kroemer, G. Trial watch: toll-like receptor ligands in cancer therapy. Oncoimmunology 12, 2180237 (2023).
Amouzegar, A., Chelvanambi, M., Filderman, J. N., Storkus, W. J. & Luke, J. J. STING agonists as cancer therapeutics. Cancers 13, 2695 (2021).
Su, T. et al. STING activation in cancer immunotherapy. Theranostics 9, 7759–7771 (2019).
Kumar, V. Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets. Int. Immunopharmacol. 89, 107087 (2020).
Hamid, O., Ismail, R. & Puzanov, I. Intratumoral immunotherapy — update 2019. Oncologist 25, e423–e438 (2019).
Rodell, C. B. et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng. 2, 578–588 (2018).
Huang, L., Ge, X., Liu, Y., Li, H. & Zhang, Z. The role of toll-like receptor agonists and their nanomedicines for tumor immunotherapy. Pharmaceutics 14, 1228 (2022).
Gadd, A. J. R., Greco, F., Cobb, A. J. A. & Edwards, A. D. Targeted activation of toll-like receptors: conjugation of a toll-like receptor 7 agonist to a monoclonal antibody maintains antigen binding and specificity. Bioconjug. Chem. 26, 1743–1752 (2015).
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results. https://www.businesswire.com/news/home/20220331005874/en/Silverback-Therapeutics-Updates-Strategic-Priorities-and-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results (2022).
Doctor, V. Silverback Halts Oncology Programs, lays off 27% of staff. BioSpace https://www.biospace.com/article/silverback-halts-oncology-programs-lays-off-27-percent-of-staff/ (2022).
Janku, F. et al. 378 A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies. J. Immunother. Cancer 8 (Suppl. 3), A230 (2020).
Janku, F. et al. Preclinical characterization and phase I study of an anti-HER2-TLR7 immune-stimulator antibody conjugate in patients with HER2+ malignancies. Cancer Immunol. Res. 10, 1441–1461 (2022).
Ackerman, S. E., Alonso, M. N., Jackson, D. Y., Lee, A. & Engleman, E. G. Immunoconjugates targeting HER2. World Patent WO2020190725A1 (2020).
Bolt Biotherapeutics. Bolt biotherapeutics initiates phase 2 clinical studies of BDC-1001 in patients with HER2-positive cancer. https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-initiates-phase-2-clinical-studies-bdc-1001 (2023).
Li, B. T. et al. A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors. J. Clin. Oncol. 41, 2538–2538 (2023).
Blum, L. K. et al. The CEA-targeted ISAC, BDC-2034, shows preclinical efficacy associated with innate immune activation, phagocytosis, and myeloid reprogramming. Cancer Res. 82 (Suppl. 12), Abstr. 2911 (2022).
Kenkel, J. A. et al. PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models. Cancer Res. 82 (Suppl. 12), Abstr. 4252 (2022).
He, L. et al. Immune modulating antibody-drug conjugate (IM-ADC) for cancer immunotherapy. J. Med. Chem. 64, 15716–15726 (2021).
Fang, S. et al. Design and characterization of immune-stimulating imidazo[4,5-c]quinoline antibody-drug conjugates. Mol. Pharm. 19, 3228–3241 (2022).
Kuo, T. C. et al. TAC-001, a toll-like receptor 9 (TLR9) agonist antibody conjugate targeting B cells, promotes anti-tumor immunity and favorable safety profile following systemic administration in preclinical models. Cancer Res. 81 (Suppl. 13), Abstr. 1721 (2021).
Pons, J. et al. Transglutaminase-mediated conjugation. US Patent US20230130194A1 (2023).
Perez, C. et al. INCLINE-101, a phase 1/2, open label, dose escalation and expansion study of TAC-001 (a TLR9 agonist conjugated to a CD22 antibody) in patients with select advanced or metastatic solid tumors. J. Immunother. Cancer 10 (Suppl. 2), A788 (2022).
Zhu, Y. et al. STING: a master regulator in the cancer-immunity cycle. Mol. Cancer 18, 152 (2019).
Woo, S.-R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830–842 (2014).
Woo, S.-R., Corrales, L. & Gajewski, T. F. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 36, 250–256 (2015).
Ohkuri, T. et al. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol. Res. 2, 1199–1208 (2014).
Demaria, O. et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc. Natl Acad. Sci. USA 112, 15408–15413 (2015).
Wu, Y.-T. et al. Tumor-targeted delivery of a STING agonist improvescancer immunotherapy. Proc. Natl Acad. Sci. USA 119, e2214278119 (2022).
Bukhalid, R. A. et al. Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines. Cancer Res. 80 (Suppl. 16), Abstr. 6706 (2020).
Duvall, J. R. et al. XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity. Cancer Res. 81 (Suppl. 13), Abstr. 1738 (2021).
Ramanjulu, J. M. et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature 564, 439–443 (2018).
Mersana Therapeutics. Mersana Therapeutics announces FDA has lifted clinical hold on phase 1 clinical trial of XMT-2056. Mersana Therapeutics https://ir.mersana.com/news-releases/news-release-details/mersana-therapeutics-announces-fda-has-lifted-clinical-hold (2023).
Konstantinidou, M. et al. PROTACs – a game-changing technology. Expert Opin. Drug Discov. 14, 1255–1268 (2019).
Kelm, J. M. et al. PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy. Mol. Cancer 22, 62 (2023).
An, S. & Fu, L. Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs. EBioMedicine 36, 553–562 (2018).
Liu, Z. et al. An overview of PROTACs: a promising drug discovery paradigm. Mol. Biomed. 3, 46 (2022).
Békés, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181–200 (2022).
Shorstova, T., Foulkes, W. D. & Witcher, M. Achieving clinical success with BET inhibitors as anti-cancer agents. Br. J. Cancer 124, 1478–1490 (2021).
Trojer, P. & Targeting, B. E. T. Bromodomains in cancer. Annu. Rev. Cancer Biol. 6, 313–336 (2022).
Liu, Z. et al. Drug discovery targeting bromodomain-containing protein 4. J. Med. Chem. 60, 4533–4558 (2017).
Pillow, T. H. et al. Antibody conjugation of a chimeric BET degrader enables in vivo activity. ChemMedChem 15, 17–25 (2020).
Min, J.-H. et al. Structure of an HIF-1alpha–pVHL complex: hydroxyproline recognition in signaling. Science 296, 1886–1889 (2002).
Hon, W.-C. et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417, 975–978 (2002).
Maneiro, M. A. et al. Antibody–PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4. ACS Chem. Biol. 15, 1306–1312 (2020).
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P. & Goldenberg, D. M. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin. Cancer Res. 17, 3157–3169 (2011).
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A. & Sharkey, R. M. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget 6, 22496–22512 (2015).
Cardillo, T. M. et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug. Chem. 26, 919–931 (2015).
Dragovich, P. S. et al. Antibody-mediated delivery of chimeric BRD4 degraders. Part 1: exploration of antibody linker, payload loading, and payload molecular properties. J. Med. Chem. 64, 2534–2575 (2021).
Dragovich, P. S. et al. Antibody-mediated delivery of chimeric BRD4 degraders. Part 2: improvement of in vitro antiproliferation activity and in vivo antitumor efficacy. J. Med. Chem. 64, 2576–2607 (2021).
Chuang, S.-H. et al. Antibody protac conjugates. US Patent US20210015942A1 (2021).
Dragovich, P. S. et al. Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα). Bioorg. Med. Chem. Lett. 30, 126907 (2020).
Thompson, P. A., Edris, B., Coburn, C. A. & Baum, P. R. Antibody construct conjugates. World Patent WO2018227023A1 (2018).
Dragovich, P. S., Baker Dockrey, S. A., Pillow, T. H. & Zhang, D. Antibody-conjugated chemical inducers of degradation of brm and methods thereof. World Patent WO2022020288A1 (2022).
Palacino, J. et al. ORM-5029: a first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer. Cancer Res. 82 (Suppl. 12), Abstr. 3933 (2022).
Saini, S. et al. Development of RNAscope multiplex-based assay for exploratory pharmacodynamic biomarkers assessment in breast cancer patients from phase I clinical trial of ORM-5029, a potent GSPT1 degrader. Cancer Res. 83 (Suppl. 7), Abstr. 2118 (2023).
Palacino, J. et al. ORM-6151: a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for AML. Blood 140, 3061–3062 (2022).
Palacino, J. et al. ORM-6151: a first-in-class CD33-antibody enabled GSPT1 degrader for AML. Cancer Res. 83 (Suppl. 7), Abstr. 2700 (2023).
Fishkin, N. & Park, P. U. Neodegrader conjugates. World Patent WO2021198965A1 (2021).
Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 535, 252–257 (2016).
Hughes, S. J. & Ciulli, A. Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders. Essays Biochem. 61, 505–516 (2017).
Ju, Y. et al. ORM-5029: discovery of an antibody drug conjugate with first-in-class molecular glue degrader warhead for treatment of HER2-positive breast cancer | Poster Board #3753. https://acs.digitellinc.com/sessions/584447/view (2023).
Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B. & Wells, J. A. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. J. Am. Chem. Soc. 143, 593–598 (2021).
Marei, H. et al. Antibody targeting of E3 ubiquitin ligases for receptor degradation. Nature 610, 182–189 (2022).
Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291–297 (2020).
Ahn, G. et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 17, 937–946 (2021).
Zebisch, M. et al. Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist R-spondin. Nat. Commun. 4, 2787 (2013).
Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the Rosetta stone of therapy resistance. Cancer Cell 37, 471–484 (2020).
Levengood, M. R. et al. Orthogonal cysteine protection enables homogeneous multi-drug antibody-drug conjugates. Angew. Chem. Int. Ed. Engl. 56, 733–737 (2017).
O’Brien, C. et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 68, 5380–5389 (2008).
Chen, R. et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol. Cancer Ther. 14, 1376–1384 (2015).
Okeley, N. M. et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin. Cancer Res. 16, 888–897 (2010).
Li, F. et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 76, 2710–2719 (2016).
Doronina, S. O. et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug. Chem. 17, 114–124 (2006).
Walker, J. A. et al. Substrate design enables heterobifunctional, dual “click” antibody modification via microbial transglutaminase. Bioconjug. Chem. 30, 2452–2457 (2019).
Sabbaghi, M. et al. Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer. Clin. Cancer Res. 23, 7006–7019 (2017).
Cilliers, C., Menezes, B., Nessler, I., Linderman, J. & Thurber, G. M. Improved tumor penetration and single-cell targeting of antibody-drug conjugates increases anticancer efficacy and host survival. Cancer Res. 78, 758–768 (2018).
Yuan, R. et al. 2022 – Abstract and Poster Presentation: Th42 – Next-generation immunostimulatory antibody-drug conjugate (iADC) combines direct tumor killing and innate immune stimulation to provide protective anti-tumor immunity (2022).
Kumar, A. et al. Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads. Bioorg. Med. Chem. Lett. 28, 3617–3621 (2018).
Nilchan, N. et al. Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine/cysteine conjugation. Antib. Ther. 2, 71–78 (2019).
Tang, C. et al. One-pot assembly of dual-site-specific antibody–drug conjugates via glycan remodeling and affinity-directed traceless conjugation. Bioconjug. Chem. 34, 748–755 (2023).
Acknowledgements
The authors acknowledge support from the US NIH (R35GM138264 and R01CA283876 to K.T.) and the US Department of Defense Breast Cancer Research Program (W81XWH-19-1-0598 to K.T.).
Author information
Authors and Affiliations
Contributions
All authors made a substantial contribution to all aspects of the preparation of this manuscript.
Corresponding author
Ethics declarations
Competing interests
All authors are named inventors on all or some of the patent applications (WO2018218004A1, US11629122B2, EP3630189A4 and WO2023122587A3) relating to the linker technologies described in this article. K.T. is a co-founder of and holds equity in CrossBridge Bio.
Peer review
Peer review information
Nature Reviews Clinical Oncology thanks N. Tumey and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Tsuchikama, K., Anami, Y., Ha, S.Y.Y. et al. Exploring the next generation of antibody–drug conjugates. Nat Rev Clin Oncol 21, 203–223 (2024). https://doi.org/10.1038/s41571-023-00850-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00850-2
This article is cited by
-
Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis
Cancer and Metastasis Reviews (2025)
-
Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing
Current Oncology Reports (2025)
-
Trop2-targeted therapy in breast cancer
Biomarker Research (2024)
-
Antibody–drug conjugates and immune checkpoint inhibitors in cancer treatment: a systematic review and meta-analysis
Scientific Reports (2024)
-
Cancer therapy with antibodies
Nature Reviews Cancer (2024)